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risk. Automated edit checks of primary data endpoints should be programmed into 
the EDC system prompting data abstractors to revise erroneous data and/or confirm 
data outside of expected ranges at entry. To confirm abstracted data reflect source 
documents (patient medical charts), a second abstractor at the site can re-abstract 
pre-defined critical study variables from patient medical charts for cross-referencing 
for data discrepancies. Site training must be effective to ensure compliance with 
chart abstraction and data quality requirements. ConClusions: Given the fre-
quent incomplete or poor quality medical chart information and the potential for 
human error in data abstraction and entry processes, data quality control methods 
are paramount. Approaches to protocol, CRF and study training materials design 
can positively impact data quality.
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objeCtives: Health technology assessment typically involves consideration of mul-
tiple conflicting criteria. Therefore, trade-offs are required between different objec-
tives such as maximizing health, restricting budget impact, increasing health equity 
and maximizing safety. Methods such as multiple decision criteria analysis (MCDA) 
are therefore increasingly being used to reflect such trade-offs in a transparent 
and consistent manner. Although MCDA can be combined with cost-effectiveness 
analysis it may, however, invalidate results from Value of Information (VOI) analysis 
when it also includes other health-related or cost-related objectives. Methods: In 
two case studies we first applied VOI methods directly and only to cost-effectiveness 
estimates, and then also applied these methods separately to all relevant deci-
sion criteria. In a simulation study on two drugs we calculated the expected value 
of perfect information (EVPI) with drug selection concerning a trade-off between 
cost-effectiveness and drug safety. In a clinical study on the primary prevention of 
cardiovascular disease using improved versus standard risk prediction we calculated 
the EVPI with selection of the best risk prediction strategy concerning a trade-off 
between cost-effectiveness and budget impact. Results: In our simulation study 
we found EVPI estimates per patient based only on cost-effectiveness were up to 
€ -586 lower and € +459 higher compared to EVPI estimates also acknowledging 
the safety criterion, depending on its weight. In our clinical study, the EVPI esti-
mates based only on cost-effectiveness were consistently lower, up to € -540 per 
patient, compared to EVPI estimates also acknowledging the budget impact cri-
terion. ConClusions: When decisions are based not only on cost-effectiveness 
but on other criteria as well, some of which also relate to costs or health effects, 
standard VOI estimates are no longer valid. However, separate application of VOI 
methods to each of the relevant decision criteria is straightforward and can facilitate 
transparent research prioritization in a complex MCDA context.
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The benefits and value of new cancer treatments often focus on the overall survival 
(OS) gains that patients may derive. Trials are typically not long enough to allow 
detailed understanding of OS, and potential benefits must be inferred from benefits 
on progression-free-survival (PFS). This raises questions such as whether early or later 
progression impacts survival, whether the increase in mortality following progression 
is sustained or gradually diffused, and whether a benefit observed on PFS implies a 
benefit in OS. Answering these questions requires an analytical framework in which 
progression and survival can be analyzed together and parameterized to address key 
questions. We propose a statistical modeling framework based on Cox regression and 
time-dependent predictors and effects. A simple formulation of this model would 
include a time-dependent indicator for progression, whose coefficient would meas-
ure the increase in risk of death following the event. This is very limiting, however; 
it assumes that the timing of progression does not matter and that the increase in 
risk of death is sustained indefinitely. A more flexible formulation can be built using 
two descriptors of event: the timing of progression (TP) and time since progression 
(TSP). These can be continuous measures or categorized (e.g., early vs. late TP), as 
appropriate. The coefficient for TP reveals whether later progression is associated 
with higher/lower subsequent mortality, while the coefficient of TSP reflects whether 
and for how long the increase/decrease in mortality is sustained and whether it ever 
returns to the level of patients who had not progressed. The impact of treatment can 
be captured on each of these parameters separately. The proposed framework will 
be illustrated with an example, and extension of the approach to other applications 
(e.g., measuring the impact of a stroke on survival) will be discussed.
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Despite the availability of a large body of research evidence on patient preferences 
for health outcomes and/or health care services, its use in health care policy deci-
sions is limited. This contrasts with the current increasing attention for patient-cen-
the use of e-health interventions.*Both B. F. M. Wijnen and L. A. M. Leenen con-
tributed equally to this work.
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objeCtives: In the absence of secondary sources of health care data, chart review 
studies can result in patient level data repositories including patient characteris-
tics, care patterns, treatment effectiveness and clinical and safety outcomes. Data 
can be used to populate economic evaluations, and value dossiers, and inform 
drug safety assessments. For successful implementation, however, knowledge of 
country-specific ethics and regulatory approval processes is paramount. Methods: 
Operational, ethics and regulatory issues and considerations as well as strategies for 
study success have been summarized in the context of eleven recent multi-national 
chart review case studies. Results: Two of 11 studies also collected data prospec-
tively; two studies were categorized as post authorization safety studies and three 
studies were conducted in peri-approval compassionate use program populations. 
The majority of studies (9) were oncology focused, with two studies focused on 
infectious diseases and opioid-induced constipation. Sample sizes varied from 20 
to 500 patients, the number of countries from 1 to 8, and the number of sites from 4 
to 61. All studies included at least one European country. Across studies, key opera-
tional considerations that impacted the ethical/regulatory approval process were 
ambiguous/amorphous multinational regulatory requirements/guidelines; com-
mercial availability or non-availability of the sponsor product at the time of chart 
abstraction; data collection method(s) (i.e., retrospective vs. hybrid chart review plus 
prospective data collection); country variation in informed consent requirements 
and definitions of personal data; and multinational contractual requirements with 
the participating sites. ConClusions: International chart review studies are an 
effective methodology to resolve data gaps not solved by existing secondary health 
care data sources resulting in tailored, patient-level datasets. Current knowledge of 
the highly variable and evolving global regulatory requirements, as well as the devel-
opment of a risk management plan informed by methodological and operational 
lessons learned at study-outset will facilitate risk mitigation and allow researchers 
to overcome key challenges.
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objeCtives: In addition to study outcome concerns arising from patients lost to 
follow-up (LFU) in pharmacoepidemiology and pharmacovigilance studies, the 
financial impact of LFU can be significant. Our objectives were to estimate cost 
per patient in Non-interventional studies, to identify variables that may affect this 
patient cost, to estimate cost of patient lost to follow-up (LFU), and financial benefits 
that can be expected from LFU minimization through Direct to Patient Contact ser-
vice (DPC). Methods: Analysis of 2013 proposals and budgets submitted to study 
sponsors. Selection criteria: non interventional, prospective, longitudinal patient fol-
low-up, full CRO services. Analysis were performed according to patient sample size, 
study duration, disease category, and different hypothesis for LFU rates. Results: 
1) 20 studies (Domestic, Regional or Global) met all inclusion criteria; 2) Annual 
cost per patient -ranging from € 1,068 to € 4,370- decreases as the study duration 
increases (set-up cost is more diluted in the patient annual cost). But the longer the 
study is the more expensive the overall cost per patient; 3) Mean annual patient cost 
significantly differs according to rarity of disease/population; rarity is an important 
criterion that greatly impacts overall and annual patient cost, especially for study 
lasting more than 1 year. Below 1 year, the cost per patient remains quite similar 
between types of diseases/populations; 4) Cost are more significant in rare diseases 
studies, therefore DPC can provide the best overall cost savings in these populations; 
and 50 The cost savings are depended on the expected rate of patient LFU-with/
without DPC service and the planned patient sample size. ConClusions: Return 
On Investment plays an important role for Sponsors to determine if DPC is valu-
able in a study. The financial investment may be beneficial regardless of the cost to 
insure completion of the patients, thus meeting the scientific study objectives. But 
it could generate cost savings as well.
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objeCtives: Retrospective chart review studies can result in robust naturalistic 
data to inform evaluations of treatment patterns, resource utilization, costs of care, 
clinical outcomes and safety. Data quality control is challenging both as a result of 
poor quality documentation in the usual care medical chart, or as a result of data 
abstraction and data entry processes. Methods: Ten chart review case studies con-
ducted in the United States, Canada and Europe were evaluated to provide recom-
mendations for improving chart review data quality control mechanisms. Results: 
All 10 studies used electronic data capture (EDC) systems. Common lessons learned 
across the studies were that the case report forms (CRFs) should only include neces-
sary data points required to fulfill the analysis. Direct chart-to-EDC data entry and 
remote real-time data quality control is recommended to reduce additional tran-
scription errors that may occur if using paper CRFs. It is important to ensure the EDC 
system includes a cohort-control platform that enables selection of patient cohorts 
(i.e., random selection) and tracking of eligibility screening to reduce selection bias 
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Cost-effectiveness models often require the consideration of a sequence of treat-
ments. This enables the downstream implications of a treatment to be captured, and 
alternative sequences to be compared. However, when many treatments are available, 
the number of feasible sequences can be large. Also, if the objective is to maximise net 
benefit for a given ICER threshold, then a comparative analysis to identify the optimal 
sequence may not be possible. This is further compounded when using individual 
patient simulation (IPS), because of the increased computational burden compared 
with cohort approaches. The aim of this study was to undertake a systematic review 
of optimisation methods that are applicable to a treatment sequencing IPS model. 
28 key papers were identified across a range of academic subjects. Metaheuristics 
including simulated annealing, tabu search and genetic algorithms have been 
applied to simulation-optimisation problems and a bespoke review framework was 
applied to determine their appropriateness. Based on the review, a framework for 
the economic evaluation of treatment sequences was developed. The framework 
considers the requirements of a cost-effectiveness model to efficiently evaluate 
sequences, the application of the reviewed metaheuristics to determine the optimal 
sequence, and the consideration of these results within a decision-making context. 
This will be applied to a case study in rheumatoid arthritis. Alternative metaheuris-
tic algorithms will be applied in an attempt to estimate a (near) optimal treatment 
sequence. Preliminary results of these experiments will be available in time for the 
November 2014 ISPOR conference. If these methods prove successful and feasible, 
then the framework may have potential applicability to sequencing models in many 
diseases. Whether there is the capability for it to be applicable within the current 
process for decision-making organisations such as NICE remains an open question, 
however, identifying an optimal sequence in a decision problem is of interest to 
decision makers.
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bACkgRound: Common indirect treatment comparison (ITC) methodology in over-
active bladder involves combining absolute reduction in urge urinary incontinence 
(UUI) episodes at study endpoint (e.g., week 12) to estimate the overall treatment 
effect. Trials with differing endpoints must assume equivalence to be included in 
the network. Further, analyses of endpoint data are not sufficient to predict efficacy 
at intermediate time points (e.g. 4 or 6 weeks). We developed and tested an alternate 
methodology to utilize available intermediate time points into an ITC of published 
studies of fesoterodine and tolterodine. Methodology: Study-level mean UUI 
reduction over time can be represented as the percent reduction from baseline, 
which can be modeled as a monotonically-increasing function with a theoretical 
maximum of 100%. This function is expressed with two parameters: %red = bi*time/ 
(ci + time), where bi is the maximum possible reduction for treatment i, and ci is the 
time required to reach half the maximum reduction. The inverse %red is a linear 
function of 1/time that can be used within a Bayesian ITC framework to generate 
a placebo-adjusted indirect comparison of efficacy. ConClusions: The endpoint 
results obtained from the alternate methodology were comparable to those obtained 
from an endpoint ITC. This novel methodology has the additional advantage of 
utilizing all available time point data within a single analysis, which can then be 
used to generate efficacy estimates at intermediate time points, which may be 
utilized within economic models. Limitations include unavailability of uncertainty 
estimates of the %red variable and difficulty of estimating combinations of param-
eters within functional constraints. Finally, our alternate methodology may be used 
for any longitudinal data exhibiting a monotonic increase or decrease and may be 
expanded to include a network with multiple treatments.
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Bayesian modelling for cost-effectiveness data has received much attention in 
both the health economics and the statistical literature, in recent years. Cost-
effectiveness data are characterised by a relatively complex structure of relation-
ships linking a suitable measure of clinical benefit (\eg QALYs) and the associated 
costs. Simplifying assumptions, such as (bivariate) normality of the underlying dis-
tributions are usually not granted, particularly for the cost variable, which is charac-
terised by markedly skewed distributions. In addition, individual-level datasets are 
often characterised by the presence of structural zeros in the cost variable. Hurdle 
models can be used to account for the presence of excess zeros in a distribution and 
have been applied in the context of cost data. We extend their application to cost-
effectiveness data, defining a full Bayesian specification which consists of a pattern 
model for the individual probability of null costs, a marginal model for the costs 
and a conditional model for the measure of effectiveness (given the observed costs). 
The model is presented using a working example to describe its main features. In 
addition, we present a R package (BCEs0) that directly implements this framework 
and can be used to run a full Bayesian cost-effectiveness analysis of individual data 
in the presence of structural zero costs for some subjects.
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Prioritisation of assessment topics is an essential activity within HTA. Failure to 
successfully identify technologies that are likely to have the greatest impact on 
the health system carries an opportunity cost that is measured in poorer decision 
tred care and integration of the patient perspective in health care policy decisions. 
A major challenge for the integration of evidence on patient preference is that 
research on patient preferences is performed by various disciplines (e.g. psychology 
and economics) that do not share a common language. It has been recommended to 
perform conceptual and taxonomic work on the definition and conceptualisation 
of ‘preference’ and related terms. The aim of this study was to develop a taxonomy 
of preference-related terms. The taxonomy was developed in three steps: 1) the 
identification of preference-related terms; 2) providing all identified terms with 
a definition from the dictionary; and 3) the identification of dominant theories 
or models from (health) economics and psychology that deal with the reference-
related terms. The proposed taxonomy consists of several building blocks that hold 
all identified preference-related terms and demonstrate the relation between terms. 
The building blocks are centred around a factual event. Ex ante to this factual event 
lies building block 1, “decision making” holding terms like “choice” and “decision”. 
Ex post lie building block 2 “evaluation process” and building block 3 “outcome of 
evaluation process”. Building block 3 holds terms like “utility”, “quality of life” and 
“satisfaction”. Building blocks 1-3 are influenced by building block 4 “the value 
system”. This value system is divided in cognition, affect and conation and holds 
terms like “beliefs”, “expectation”, “attitudes”, “desires” and “intention”. In this tax-
onomy, preferences can be considered as a part of the value system. The proposed 
taxonomy is a first step towards conceptual clarity to facilitate the integration of 
research evidence in health care policy decisions.
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Overall survival (OS) is traditionally modelled in economic evaluations of anti-cancer 
drugs. However, OS is commonly associated with problems such as immaturity of the 
data, or confounding due to treatment switching or use of inappropriate treatments 
after progression. Fortunately, analysis of historical trials reveals that there is good 
evidence across a range of cancers that the mean time in post-progression survival 
(PPS) is equal between treatment arms, i.e. Δ PPS = 0. Therefore, we recommend that 
the default position is to assume equal mean times post-progression. If there is no 
a priori biological reason to suppose that the PPS times are likely to differ between 
treatments (e.g. due to differences in cross-resistance or long term toxicities between 
treatments), our recommendation is that it should be assumed that the mean time in 
progressive disease is equal between treatment arms if any of the following apply: OS 
is very immature; treatments post-progression are substantially imbalanced between 
treatment arms; in particular, treatment switching has occurred at progression; treat-
ments post-progression are different to those routinely given in clinical practice; only 
single arm trials are available. If none of the above apply, or if there are a priorireasons 
to suggest that Δ PPS differs from 0, then the recommendation is to model OS and PFS 
in the traditional way. For chronic cancers, it is recommended that analyses should 
either assume equal times post initial treatment or equal time post progression. The 
assumption that Δ PPS = 0 substantially simplifies the economic analysis because 
cost-effectiveness becomes insensitive to OS. The methodology has been endorsed 
twice by NICE appraisal committees in assessments of drugs for chronic myeloid 
leukaemia. The cost-effectiveness of several drugs recently assessed by NICE are 
re-calculated using the methods proposed. Next, we give simplified formulae for the 
maximum drug price acceptable for reimbursement under the methodology.
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Various online services such as Socialbakers, Keyhole, Gnip offer tools to analyze, 
fetch and collect data from social media. This data is often presented in a form 
of interactive web based dashboards, displaying various trends: number of posts, 
mentions, shares, likes over time. Facebook and Twitter have an API to access data 
on social media profiles of real people. Users profiles usually have data on age, 
sex, employment and relationships status, specific group membership, etc. We 
conducted a simple feasibility study using Facebook API in diabetes area using 
profiles of people posting hashtags as a primary source of data. We then expanded 
the sample by adding people who liked, shared and reposted messages containing 
diabetes relaed hashtags #Diabetes, #dedoc, #ourD. We applied exclusion criteria 
to derive a sample consisting of patients only, hence targeting specific group of 
people. Our assumption was that people who interact with posts containing spe-
cific hashtag have diabetes. We used descriptive statistics to characterize obtained 
sample (n= 17296) by calculating mean age, age distribution histogram, proportion 
of males and females and other descriptive metrics. We also calculated conditional 
probabilities of being in multiple disease area Facebook groups such as obesity 
groups or groups of people with increased risk of cardiovascular disease. Future 
area of research will be concentrated on aspects of in-degree centrality in net-
work of diabetic people, hypothesis testing between two different groups, analyses 
of changes in positive/negative posting trends following drug launch, locating 
agents and influencers in the network and conducting prospective studies in 
social media using hashtags. Social Media data can be a valuable addition to a 
real life post launch data. Evidence on changes in positive/negative postings can 
be used as an additional piece of information in Phase IV studies or risk-sharing 
agreements.
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